Afatinib in EGFR TKI-naive patients (pts) with locally advanced/metastatic NSCLC harbouring EGFR mutations: An interim analysis of a phase IIIB trial

被引：0
|
作者：
Passaro, A. [1 ]
Laktionov, K. K. [2 ]
Poltoratskiy, A. [3 ]
Egorova, I. [4 ]
Hochmair, M. [5 ]
Migliorino, M. R. [6 ]
Metro, G. [7 ]
Gottfried, M. [8 ]
Tsoi, D. [9 ]
Ostoros, G. [10 ]
Rizzato, S. [11 ]
Mukhametshina, G. Z. [12 ]
Schumacher, M. [13 ]
Novello, S. [14 ]
Dziadziuszko, R. [15 ]
Tang, W. [16 ]
Clementi, L. [17 ]
Cseh, A. [18 ]
Kowalski, D. [19 ]
De Marinis, F. [1 ]
机构：
[1] European Inst Oncol, Milan, Italy
[2] Russian Acad Med Sci, Moscow, Russia
[3] Petrov Res Inst Oncol, St Petersburg, Russia
[4] Clin Oncol Dispensary, St Petersburg, Russia
[5] Otto Wagner Hosp, Vienna, Austria
[6] San Camillo Forlanini Hosp, Rome, Italy
[7] Santa Maria Misericordia Hosp, Perugia, Italy
[8] Tel Aviv Univ, Tel Aviv, Israel
[9] St John God Murdoch Hosp, Murdoch, WA, Australia
[10] Natl Koranyi Inst Pulmonol, Budapest, Hungary
[11] Azienda Sanit Univ Integrata, Udine, Italy
[12] Minist Hlth Republ Tatarstan, Kazan, Russia
[13] Ordensklinikum Elisabethinen, Linz, Austria
[14] Univ Turin, Turin, Italy
[15] Med Univ Gdansk, Gdansk, Poland
[16] Boehringer Ingelheim Pharmaceut Inc, 90 E Ridge POB 368, Ridgefield, CT 06877 USA
[17] Boehringer Ingelheim Italia SpA, Milan, Italy
[18] Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria
[19] Oncol Ctr & Inst, Warsaw, Poland
来源：
ANNALS OF ONCOLOGY | 2019年 / 30卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
115O
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Clinical outcomes in patients with EGFR mutations: pooled analysis of NSCLC patients treated with either an EGFR TKI or chemotherapy
    Paz-Ares, L.
    Soulieres, D.
    Klughammer, B.
    Melezinek, I.
    Moecks, J.
    Keil, L.
    Mok, T.
    EJC SUPPLEMENTS, 2009, 7 (02): : 551 - 552
  • [32] Intercalated EGFR and Chemotherapy in Locally Advanced NSCLC with EGFR Mutations: Data on 5 Patients and Clinical Study
    Griesinger, Frank
    Roeper, Julia
    Lueers, Anne
    Falk, Markus
    Hallas, Cora
    Tiemann, Markus
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S871 - S871
  • [33] A Phase II Study of Afatinib Treatment for Elderly Patients with Previously Untreated Advanced NSCLC Harboring EGFR Mutations
    Suzuki, K.
    Imai, H.
    Kaira, K.
    Anzai, M.
    Tsuda, T.
    Ishizuka, T.
    Kuwako, T.
    Naruse, I.
    Nemoto, K.
    Uchino, J.
    Morozumi, N.
    Ishihara, S.
    Minato, K.
    Hisada, T.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S498 - S498
  • [34] Efficacy and Safety of EGFR-TKI Rechallenge Treatment in Elderly Patients with Advanced NSCLC Harboring Sensitive EGFR Mutations
    Yamada, Y.
    Imai, H.
    Minemura, H.
    Sugiyama, T.
    Kaira, K.
    Kanazawa, K.
    Kasai, T.
    Minato, K.
    Kaburagi, T.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S943 - S943
  • [35] Letter to the editor concerning first-line therapy with afatinib - an irreversible EGFR TKI and overall survival of NSCLC patients with EGFR gene mutations
    Krawczyk, Pawel
    Powrozek, Tomasz
    Nicos, Marcin
    Milanowski, Janusz
    WSPOLCZESNA ONKOLOGIA-CONTEMPORARY ONCOLOGY, 2015, 19 (03): : 250 - 251
  • [36] A phase I trial of afatinib (Afa) and bevacizumab (Bev) in chemo-naive patients (pts) with advanced non-small-cell lung cancer (NSCLC) harboring EGFR-mutations: OLCSG1404
    Harada, D.
    Nogami, N.
    Kozuki, T.
    Ninomiya, T.
    Bessho, A.
    Kuyama, S.
    Fujimoto, N.
    Sugimoto, K.
    Aoe, K.
    Ochi, N.
    Minami, D.
    Fukamatsu, N.
    Kudo, K.
    Kiura, K.
    ANNALS OF ONCOLOGY, 2017, 28
  • [37] Updated analysis of a phase I trial of afatinib (Afa) and bevacizumab (Bev) in chemo-naive patients (pts) with advanced non-small cell lung cancer (NSCLC) harboring EGFR-mutations: OLCSG1404
    Ninomiya, T.
    Nogami, N.
    Kozuki, T.
    Harada, D.
    Kubo, T.
    Ohashi, K.
    Kuyama, S.
    Kudo, K.
    Bessho, A.
    Fujimoto, N.
    Aoe, K.
    Shibayama, T.
    Minami, D.
    Sugimoto, K.
    Ochi, N.
    Takigawa, N.
    Hotta, K.
    Kiura, K.
    ANNALS OF ONCOLOGY, 2019, 30 : 626 - 626
  • [38] Rationale and Design of a Phase II Trial of Dacomitinib in Advanced NSCLC Patients with Uncommon EGFR Mutations
    Han, B.
    Zhang, B.
    Shi, C.
    Gao, Z.
    Zhong, H.
    Xiong, L.
    Gu, A.
    Wang, W.
    Chu, T.
    Zhang, W.
    Wang, H.
    Zhang, X.
    Zhong, R.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S613 - S613
  • [39] Phase I study (BLOOM) of AZD3759, a BBB penetrable EGFR inhibitor, in patients with TKI-naive, EGFRm NSCLC with CNS metastases.
    Ahn, Myung-Ju
    Kim, Dong-Wan
    Cho, Byoung Chul
    Kim, Sang-We
    Lee, Jong-Seok
    Ahn, Jin Seok
    Kim, Tae Min
    Lin, Chia-Chi
    Kim, HyeRyun
    John, Tom
    Kao, Stephen Chuan-Hao
    Goldman, Jonathan Wade
    Su, Wu-Chou
    Natale, Ronald B.
    Overend, Philip
    Yang, Zhenfan
    Yang, James Chih-Hsin
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [40] Activity of afatinib in patients (pts) with EGFR mutation-positive (EGFRm plus ) NSCLC and baseline brain metastases: Pooled analysis of three large phase IIIb trials
    Gottfried, M.
    de Marinis, F.
    Tu, H.
    Laktionov, K. K.
    Feng, J.
    Poltoratskiy, A.
    Zhao, J.
    Tan, E-H.
    Lee, V.
    Kowalski, D.
    Yang, C-T.
    Srinivasa, B.
    Passaro, A.
    Clementi, L.
    Tang, W.
    Huang, D. C-L.
    Cseh, A.
    Park, K.
    Zhou, C.
    Wu, Y-L.
    ANNALS OF ONCOLOGY, 2019, 30
12345